Raymond James Financial
VVOS icon

Raymond James Financial’s Vivos Therapeutics VVOS Stock Holding History

Raymond James Financial’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-74
Closed -$234 – 6763
2025
Q2 		$234 Buy
+74
New +$187 ﹤0.01% 6763

Other funds holding VVOS

CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial's VVOS Position: Q3 2025 in Review

Raymond James Financial sold out of Vivos Therapeutics (VVOS) in Q3 2025, closing a stake of 74 shares — an estimated $234 sold.

Raymond James Financial first reported a position in VVOS in Q2 2025 and held it in 1 quarter. The position peaked at $234 in Q2 2025. 23 funds tracked by Wall St. Rank hold VVOS as of Q3 2025.

  • Raymond James Financial reported no remaining Vivos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 74 Vivos Therapeutics shares in Q3 2025, an estimated $234.
  • Raymond James Financial first reported a position in Vivos Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Vivos Therapeutics position peaked at $234 in Q2 2025.
  • 23 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.